Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Sangamo (SGMO) reported positive updated data from a Phase 1/2 study of its gene therapy candidate ST-920 in the treatment of Fabry disease. Read more here.

Greg Schreiner, the pianist, narrator and producer of Hollywood Revisited, will present “Out of the Closet and Into the Day — ...

A Rockville immunotherapy company struck an $8 million deal to take back ownership of the drug candidates it’s been licensing ...

Silver Spring’s United Therapeutics has scored a regulatory green light to start clinical trials for its genetically modified pig kidneys to be transplanted into humans. It's as significant for the ...

NEW YORK CITY, NY / ACCESS Newswire / February 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Sage Therapeutics (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Rockwall ISD sixth grade SAGE students recently participated in a “Pathways to Success” field trip where they had the ...

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...